Typewriter Therapeutics has emerged from stealth with $56 million in Series A funding and a pointed bet: deliver gene therapy without viruses.
Most gene therapies use viral vectors to ferry genes into cells — effective, but increasingly linked to safety problems. Typewriter’s platform, target-primed reverse transcription (TPRT), instead harnesses a natural “jumping gene” (the R2 retrotransposon) to insert therapeutic genes at specific sites, delivered as RNA in a lipid nanoparticle (LNP) — the same kind of carrier used in mRNA vaccines. The round was led by RA Capital Management and AN Venture Partners.
Where it’s aimed
Typewriter plans to focus on in vivo CAR-T (engineering cancer-fighting T cells inside the body, rather than in a lab) and hereditary liver diseases. It expects to begin non-human-primate studies by late 2026 and name a first in vivo CAR-T candidate.
Why the timing matters
The non-viral pitch lands amid real safety setbacks for viral approaches: Novartis halted a lentiviral CAR-T program after patient deaths, Bristol Myers Squibb paused autoimmune CAR-T trials over inflammatory events, and several gene-therapy programs (Sarepta, Pfizer, Intellia, Rocket, Capsida) have faced fatalities. Meanwhile, big players (J&J, Lilly, AstraZeneca, Sanofi) are pouring money into in vivo CAR-T as a simpler alternative to today’s lab-manufactured cell therapies. It’s early — preclinical — but Typewriter is riding a clear industry shift.